HLS Therapeutics Inc
TSX:HLS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sheen Tai Holdings Group Company Ltd
HKEX:1335
|
HK |
|
Haitong Unitrust International Financial Leasing Co Ltd
HKEX:1905
|
CN |
|
J
|
Jiangxi Bank Co Ltd
HKEX:1916
|
CN |
|
Transgene Biotek Ltd
BSE:526139
|
IN |
|
J
|
Jiangsu Changhai Composite Materials Co Ltd
SZSE:300196
|
CN |
|
Changzhou Tronly New Electronic Materials Co Ltd
SZSE:300429
|
CN |
HLS Therapeutics Inc
EPS (Diluted)
HLS Therapeutics Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
HLS Therapeutics Inc
TSX:HLS
|
EPS (Diluted)
$0
|
CAGR 3-Years
18%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-14%
|
|
|
M
|
Manitex Capital Inc
XTSX:MNX
|
EPS (Diluted)
CA$0
|
CAGR 3-Years
26%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
G
|
Greenrise Global Brands Inc
CNSX:XCX
|
EPS (Diluted)
€0
|
CAGR 3-Years
42%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
HLS Therapeutics Inc
Glance View
HLS Therapeutics, Inc. operates as a pharmaceutical company. The company is headquartered in Etobicoke, Ontario and currently employs 92 full-time employees. The firm is focused on developing clinically differentiated pharmaceutical products in the specialty central nervous system (CNS) and cardiovascular (CV) markets. Its products include Vascepa, Trinomia, Clozaril, CSAN Pronto, PERSERIS and MyCare Psychiatry/MyCare Insite. Its lead product, Clozaril, is an atypical antipsychotic indicated in the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules reduce the risk of cardiovascular events, such as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or hospitalization for unstable angina in statin-treated patients with elevated triglycerides.
See Also
What is HLS Therapeutics Inc's EPS (Diluted)?
EPS (Diluted)
-0.4
USD
Based on the financial report for Dec 31, 2025, HLS Therapeutics Inc's EPS (Diluted) amounts to -0.4 USD.
What is HLS Therapeutics Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
-14%
Over the last year, the EPS (Diluted) growth was 35%. The average annual EPS (Diluted) growth rates for HLS Therapeutics Inc have been 18% over the past three years , 4% over the past five years , and -14% over the past ten years .
